Sunitinib versus cabozantinib, crizotinib, or savolitinib for advanced papillary renal cell carcinoma

The randomized phase 2 SWOG1500 study found that cabozantinib resulted in significantly longer progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma (median 9.0 months versus 5.6 months; HR 0.60; p=0.019).